Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Sai Ma, PhD

Articles by Sai Ma, PhD

Insurers’ Perspectives on MA Value-Based Insurance Design Model

ByDmitry Khodyakov, PhD,Christine Buttorff, PhD,Kathryn Bouskill, PhD,Courtney Armstrong, MPH,Sai Ma, PhD,Erin Audrey Taylor, PhD,Christine Eibner, PhD

July 18th 2019

This article describes perspectives of Medicare Advantage (MA) insurers about participating in the CMS value-based insurance design model test launched in 2017.

All Things Considered, the Answer Is a Resounding Yes

ByGordon K. Norman, MD, MBA. Author reply by Soeren Mattke, MD, DSc,Michael Seid, PhD,Sai Ma, PhD

January 15th 2008

Evidence for the Effect of Disease Management: Is $1 Billion a Year a Good Investment?

BySoeren Mattke, MD, DSc,Michael Seid, PhD,Sai Ma, PhD

December 1st 2007

Latest Updated Articles

All Things Considered, the Answer Is a Resounding Yes
January 15th 2008
Evidence for the Effect of Disease Management: Is $1 Billion a Year a Good Investment?
December 1st 2007
Insurers’ Perspectives on MA Value-Based Insurance Design Model
July 18th 2019

Trending on AJMC

Tec-Dara Demonstrates Superior 3-Year PFS vs Standard Therapy in Functional High-Risk Myeloma: Rahul Banerjee, MD

MRD-Guided CLL Treatment Duration: Personalization or Malpractice?

Global Hematology Trials Ensure Research Stays Applicable, Flexible, Patient-Centered

Blinatumomab Improves Outcomes, Toxicity in High-Risk Pediatric ALL: Martin Schrappe, MD, PhD

frontMIND Trial Shows PFS Benefit With Tafasitamab, Lenalidomide Combo in High-Risk DLBCL: Umberto Vitolo, MD